Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNX281 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT04609579Phase 1Terminated
- Sponsor
- Stingthera, Inc.
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SNX281 in solid tumor (advanced stage) and lymphoma, sponsored by Stingthera, Inc. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Adverse Events and Serious Adverse Events at 20 weeks. Started Nov 2020; status: terminated.
02
Drugs
SNX281
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04609579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609579.